, Système cardiaque, anatomo-physiologie cardiaque

J. Fiorenttino and F. Oberle, Cardiologie: le fonctionnement électrique du coeur

, Collège National de Pharmacologie Médical

F. Canon, Physiologie des systèmes intégrés, les principes et fonctions-L'électrocardiogramme (ECG)

M. Dominguez and M. Dubuc, Arythmie cardiaque, guide d'apprentissage". Presses universitaires de l, vol.148, 2005.

M. T. Keating and M. C. Sanguinetti, Molecular and cellular mechanisms of cardiac arrhythmias, Cell, vol.104, issue.4, pp.569-80, 2001.

D. P. Zipes and H. J. Wellens, Sudden cardiac death". Circulation, vol.98, pp.2334-51, 1998.

L. Fauchier, N. Clementy, and D. Babuty, Antiarythmiques". EMC-Cardiologie, 2013.

C. Bohuon and C. Monneret, Fabuleux hasards: histoire de la découverte de médicaments, vol.139, 2012.

A. Hollman, Plants in cardiology, Br Heart J, vol.67, p.116, 1992.

W. Sneader, Drug Discovery: A History

V. Maby-mottet, D. Ollo, and P. Meyer, Amiodarone et thyroïde", Rev Med Suisse, vol.8, pp.2175-2180, 2012.

D. P. Zipes, E. N. Prystowsky, and J. J. Heger, Amiodarone: Electrophysiologic actions, pharmacokinetics and clinical effects, J Am Coll Cardiol, vol.3, issue.4, pp.1059-71, 1984.

S. Pourbaix, Y. Berger, and J. P. Desager, Absolute bioavailability of amiodarone in normal subjects, Clin Pharmacol Ther, vol.37, issue.2, pp.118-141, 1985.

H. Van-herendael and D. P. , Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia". Vasc Health Risk Manag, vol.6, pp.465-472, 2010.

C. C. Libersa, S. A. Brique, and K. B. Motte, Dramatic inhibition of amiodarone metabolism induced by grapefruit juice, Br J Clin Pharmacol, vol.49, issue.4, pp.373-381, 2000.

K. Ohyama, M. Nakajima, and M. Suzuki, Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions, Br J Clin Pharmacol, vol.49, issue.3, pp.244-53, 2000.

M. R. Ghovanloo, M. Abdelsayed, and P. C. Ruben, Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels, Front Pharmacol, vol.7, issue.3, pp.244-53, 2016.

B. Delhotal, J. M. Poirier, and G. Peytavin, Suivi thérapeutique pharmacologique de l'amiodarone, EMC-Biologie médicale, pp.1-3, 2006.

H. Autorité-de-la-santé, Commission de la transparence sur la cordarone®, 2012.

L. Sanofi-synthelabo, Rapport d'activite 2002-rapport-institutionnel-9339, 2002.

. Synthe_fr,

, Drug Safety Information for Heathcare Professionals-Information for Healthcare Professionals: Amiodarone, 2013.

C. W. Bedrossian, C. J. Warren, and J. Ohar, Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry, Ann Diagn Pathol, vol.1, issue.1, pp.47-56, 1997.

F. Morady, M. J. Sauve, and P. Malone, Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation, Am J Cardiol, vol.52, issue.8, pp.975-984, 1983.

K. Hack-lyoung, J. -. Bin, S. Woo-young, and C. , The incidence and predictors of overall adverse effects caused by low dose amiodarone in real-world clinical practice, Korean J Intern Med, vol.29, issue.5, pp.588-596, 2014.

M. Mäntyjärvi, K. Tuppurainen, and K. Käheimo, Ocular Side Effects of Amiodarone, Surv Ophthalmol, vol.42, issue.4, pp.360-366, 1998.

D. V. Ingram, Ocular Effects in long-term amiodarone therapy, Am Heart J, vol.106, issue.4, pp.902-907, 1983.

D. V. Ingram, N. S. Aggarao, and D. A. Chamberlain, Ocular changes resulting from therapy with amiodarone, Br J Ophthalmol, vol.66, issue.10, pp.676-685, 1982.

M. D. Margoli and R. Sharda, Le nerf optique : anatomie, fonction et maladies fréquentes

N. Guépratte and D. Lebuisson, Diagnostic d'une neuropathie optique toxique et/ou carentielle, Jr Fr Opht, issue.7, pp.765-770, 2003.

D. Albert, J. Miller, and D. Azar, Albert & Jakobiec's Principles & Practice of Ophthalmology, vol.5502, p.27, 2008.

A. Rousseau and M. Labetoulle, Atteintes ophtalmologiques des traitements systémiques, EMC-Ophtalmologie, vol.12, issue.3, pp.1-12, 2015.

G. Elmbt, C. Andris, and N. Collignon, Neuropathie optiques liées à l'amiodarone-à propos de deux cas" 26 janvier, 2007.

D. Amico, D. J. Kenyon, D. F. Ruskin, and J. N. , Amiodarone keratopathy: drug-induced lipid storage disease, Arch Ophthalmol, vol.99, issue.2, pp.257-61, 1981.

R. S. Passman, C. L. Bennett, and J. M. Purpura, Amiodarone-associated optic neuropathy: A critical review, Am J Med, vol.125, issue.5, pp.447-53, 2012.

K. Jaworski, I. Walecka, and L. Rudnicka, Cutaneous adverse reactions of amiodarone". ed Sci Monit, vol.20, pp.2369-72, 2014.

P. Vassallo and R. G. Trohman, Prescribing amiodarone: an evidence-based review of clinical indications, JAMA, vol.298, issue.11, pp.1312-1334, 2007.

V. R. Vorperian, T. C. Havighurst, and S. Miller, Adverse Effects of Low Dose Amiodarone: A Meta-Analysis, J Am Coll Cardiol, vol.30, issue.3, pp.791-799, 1997.

S. R. Punnam, S. K. Goyal, and V. P. Kotaru, Amiodarone-a "Broad Spectrum" antiarrhythmic drug, Cardiovasc Hematol Disord Drug Targets, vol.10, issue.1, pp.73-81, 2010.

A. Ammoury, S. Michaud, and C. Paul, Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin, Arch Dermatol, vol.144, issue.1, p.92, 2008.

, Institut national de la santé et de la recherche médicale

V. Maby-mottet, D. Ollo, and P. Meyer, Amiodarone et thyroïde", Rev Med Suisse, vol.8, pp.2175-2180, 2012.

S. K. Narayana, D. Woods, and J. Boos, Management of Amiodarone-Related Thyroid Problems, Ther Adv Endocrinol Metab, vol.2, issue.3, pp.115-126, 2011.

E. Martino, L. Bartalena, and F. Bogazzi, The Effects of Amiodarone on the Thyroid, Endocr Rev, 2001.

C. M. Newman, A. Price, and D. W. Davies, Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy, Heart, vol.79, issue.2, pp.121-128, 1998.

F. Osman, J. A. Franklyn, and M. C. Sheppard, Successful treatment of amiodarone-induced thyrotoxicosis, vol.105, pp.1275-1282, 2002.

L. Pham, A. J. Shaer, and T. Marnejon, Hyponatremia-a rare but serious complication of amiodarone: a case report and review of the literature, Case Rep Nephrol Urol, vol.3, pp.46-50, 2013.

C. Fayon, Docetaxel-Amiodarone: association à risque ?". Faculté de médecine, université de Lorraine, vol.146, 2003.

A. Abuzaid, M. Saad, and M. Ayan, Acute amiodarone pulmonary toxicity after drug holiday: A case report and review of the literature, Case Rep Cardiol, p.182154, 2015.

H. H. Rotmensch, M. Liron, and M. Tupilski, Possible association of pneumonitis with amiodarone therapy, Am Heart J, vol.100, issue.3, pp.412-415, 1980.

L. Wonho, R. R. Dong, and H. Seon-sook, Very early onset of amiodarone-induced pulmonary toxicity, Korean Circ J, vol.43, issue.10, pp.699-701, 2013.

P. Bonniaud, Toxicité pulmonaire de l'amiodarone, Rev Mal Resp, vol.22, pp.124-126, 2005.

C. F. Orr and J. E. Ahlskog, Frequency, characteristics, and risk factors for amiodarone neurotoxicity, Arch Neurol, vol.66, issue.7, pp.865-874, 2009.

M. E. Charness, F. Morady, and M. M. Scheinman, Frequent Neurologic Toxicity Associated with Amiodarone Therapy, Neurology, vol.34, issue.5, pp.669-71, 1984.

P. R. Palakurthy, V. Iyer, and R. J. Meckler, Unusual neurotoxicity associated with amiodarone therapy, Arch Intern Med, vol.147, issue.5, pp.881-885, 1987.

C. F. Orr and J. E. Ahlskog, Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity, Arch Neurol, vol.66, issue.7, pp.865-874, 2009.

J. Buggey, M. Kappus, and A. S. Lagoo, Amiodarone-induced liver injury and cirrhosis, ACG Case Rep J, 2015.

B. Guigui, S. Perrot, and J. P. Berry, Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease, Hepatology, vol.8, issue.5, pp.1063-1071, 1988.

, Base de données Livertox

V. R. Vorperian, T. C. Havighurst, and S. Miller, Adverse effects of low dose amiodarone: a meta-analysis, J Am Coll Cardiol, vol.30, issue.3, pp.791-799, 1997.

J. Ferguson, A. I. Dubé, and C. Ouellet, Hépatotoxicité à la suite de l'utilisation à court terme d'amiodarone pour une personne âgée: un report de cas, Can J Hosp Pharm, vol.66, issue.3, pp.190-193, 2013.

A. A. Patel, C. White, and E. L. Gillespie, Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis, Am J Health Syst Pharm, vol.63, issue.9, pp.829-866, 2006.

S. Renet, M. C. Chaumais, and T. Antonini, Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 Cases including a rechallenge, Gastroenterology, vol.149, issue.6, pp.1378-1380, 2015.

G. Sarganas, E. Garbe, and A. Klimpel, Epidemiology of symptomatic drug-Induced long QT syndrome and torsade de pointes in Germany, Europace, vol.16, issue.1, pp.101-109, 2014.

S. H. Hohnloser, T. Klingenheben, and B. N. Singh, Amiodarone associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia, Ann Intern Med, vol.121, issue.7, pp.529-564, 1994.

, Résumé des Caractéristiques du Produit. Cordarone 200 mg, comprimé sécable